Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manag Res. 2021 Jul 12;13:5523-33. doi: 10.2147/CMAR.S305939
Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, Brown M, Reaney M, Mahajan P, Guillemin I, Boguniewicz M, Pariser D. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatology. 2019 Nov 6;19(1):15. doi: 10.1186/s12895-019-0095-3
Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res. 2014 Oct 23;2014(6):437-49. doi: 10.2147/CMAR.S63603
Castellsague J, García-Rodríguez LA, Duque A, Perez-Gutthann S. Risk of severe cutaneous disorders in users of oral antifungals. BMC Dermatology. 2002 Nov 28;2(14). doi: 10.1186/1471-5945-2-14
Castellsague J, Garcia-Rodriuez LA, Duque A, Perez S. Risk of serious skin disorders among users of oral antifungals: a population-based study. BMC Dermatology. 2002;2:14.
Williams VSL, Jones LV, Tukey JW. Controlling error in multiple comparisons, with examples from state-to-state differences in educational achievement. J Educ Behav Stat. 1999;24(1):42-69. doi: 10.3102/10769986024001042